Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study. (Q48891121)

From Wikidata

Jump to navigation Jump to search

scientific article published on 22 December 2016

Language	Label	Description	Also known as
English	Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study.	scientific article published on 22 December 2016

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma-safety and efficacy in a phase II study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Thomas Kurt Eigentler

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Kilian Wistuba-Hamprecht

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

author name string

Benjamin Weide

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Alexander Martens

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Henning Zelba

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Ludwig Maier

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Bernhard D Klumpp

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Daniel Soffel

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Hans-Peter Lipp

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

publication date

22 December 2016

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Cancer Immunology, Immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

66

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

441-449

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

CTLA-4: new insights into its biological function and use in tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

The interaction properties of costimulatory molecules revisited.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

CTLA-4 is a second receptor for the B cell activation antigen B7

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Novel cancer immunotherapy agents with survival benefit: recent successes and next steps

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response.

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Final version of 2009 AJCC melanoma staging and classification

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Molecular Pathways: Mechanism of Action for Talimogene Laherparepvec, a New Oncolytic Virus Immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Management of immune-related adverse events and kinetics of response with ipilimumab

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Increased survival from stage IV melanoma associated with fewer regulatory T Cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

High response rate after intratumoral treatment with interleukin-2

1 reference

https://api.crossref.org/works/10.1007%2FS00262-016-1944-0

21 January 2018

Identifiers

10.1007/S00262-016-1944-0

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28008452%20AND%20SRC:MED&resulttype=core&format=json

1 April 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48891121&oldid=2209858669"